Loading provider…
Loading provider…
Gynecologic Oncology Physician in Orange, CA
NPI: 1265759807Primary Practice Location
UNIVERSITY OF CALIFORNIA IRVINE MEDICAL CENTER
101 The City Dr S, Orange, CA
Primary Employer
OB-GYN University Associates
uci.edu
HQ Phone
Get M.D. Jill's Phone Numberphone_androidMobile
Get M.D. Jill's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
CA State Medical License
2018 - 2025
NY State Medical License
2014 - 2019

American Board of Obstetrics and Gynecology
Obstetrics & Gynecology

American Board of Obstetrics and Gynecology
Gynecologic Oncology
Memorial Sloan Kettering Cancer Center
Fellowship • Gynecologic Oncology
2014 - 2018
Johns Hopkins University
Residency • Obstetrics and Gynecology
2010 - 2014
University of Toledo College of Medicine and Life Sciences
utoledo.edu
Medical School
Until 2010
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 145 | 309 |
| 2 | 99443Physician telephone patient service, 21-30 minutes of medical discussion | 23 | 26 |
| 3 | 99204New patient office or other outpatient visit, 45-59 minutes | 22 | 22 |
High-grade endometrial cancer: revisiting the impact of tumor size and location on outcomes.
Authors: Kemi Doll
Publication Date: 2013-06-25
Authors: Roozbeh Houshyar, Justin Glavis-Bloom, Caleb Cheng
Publication Date: 2021-05-27
Lifestyle and Weight Management Counseling in Uterine Cancer Survivors: A Study of the Uterine Cancer Action Network.
Authors: Ritu Salani
Publication Date: 2015-05-14
Lead Sponsor: Mersana Therapeutics
Intervention / Treatment: DRUG: upifitamab rilsodotin
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: BIOLOGICAL: Bevacizumab, DRUG: Paclitaxel, BIOLOGICAL: Anetumab Ravtansine